Compare YETI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YETI | IMNM |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 2016 | 2020 |
| Metric | YETI | IMNM |
|---|---|---|
| Price | $41.26 | $20.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 15 |
| Target Price | ★ $54.93 | $36.00 |
| AVG Volume (30 Days) | ★ 1.5M | 1.0M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ 1.06 | N/A |
| Revenue | ★ $1,868,494,000.00 | $6,941,000.00 |
| Revenue This Year | $7.64 | N/A |
| Revenue Next Year | $7.09 | $17,534.68 |
| P/E Ratio | $39.87 | ★ N/A |
| Revenue Growth | ★ 2.11 | N/A |
| 52 Week Low | $31.66 | $11.55 |
| 52 Week High | $53.99 | $30.06 |
| Indicator | YETI | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 42.36 | 32.99 |
| Support Level | $38.75 | $19.39 |
| Resistance Level | $43.39 | $23.25 |
| Average True Range (ATR) | 1.56 | 1.08 |
| MACD | 0.22 | -0.35 |
| Stochastic Oscillator | 31.30 | 11.87 |
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.